Name: Boc-L-Nva(3-Et)-OH
SKU: BAA3620
Availability: InStock

Grouped product items

Qty

Packing unit

Price

SKU

Availability

1 g

€350.00

BAA3620.0001

5 g

€1,400.00

BAA3620.0005

references

Discovery of Begacestat, a Notch-1-Sparing g-Secretase Inhibitor for the Treatment of Alzheimer’s Disease. S. C. Mayer, A. F. Kreft, B. Harrison, M. Abou-Gharbia, M. Antane, S. Aschmies, K. Atchison, M. Chlenov, D. C. Cole, T. Comery, G. Diamantidis, J. Ellingboe, K. Fan, R. Galante, C. Gonzales, D. M. Ho, M. E. Hoke, Y. Hu, D. Huryn, U. Jain, M. Jin, K. Kremer, D. Kubrak, M. Lin, P. Lu, R. Magolda, R. Martone, W. Moore, A. Oganesian, M. N. Pangalos, A. Porte, P. Reinhart, L. Resnick, D. R. Riddell, J. Sonnenberg-Reines, J. R. Stock, S.-C. Sun, E. Wagner, T. Wang, K. Woller, Z. Xu, M. M. Zaleska, J. Zeldis, M. Zhang, H. Zhou, and J. S. Jacobsen; J. Med. Chem. 2008; 51: 7348-7351. https://doi.org/10.1021/jm801252w.

Synthesis and structure-activity relationship of a novel series of heterocyclic sulfonamide g-secretase inhibitors. J. Pu, A. F. Kreft, S. H. Aschmies, K. P. Atchison, J. Berkowitz, T. J. Caggiano, M. Chlenov, G. Diamantidis, B. L. Harrison, Y. Hu, D. Huryn. J. S. Jacobsen, M. Jin, K. Lipinski. P. Lu. R. L. Martone, K. Morris, J. Sonnenberg-Reines, D. R. Riddell, J. Sabalski, S.-C. Sun, E. Wagner, Y. Wang, Z. Xu, H. Zhou, and L. Resnick; Bioorg. Med. Chem. 2009; 17: 4708-4717. https://doi.org/10.1016/j.bmc.2009.04.052.

Structure-activity relationships of tubulysin analogues. J. R. Courter, J. Z. Hamilton, N. R. Hendrick, M. Zaval, A. B. Waight, R. P. Lyon, P. D. Senter, S. C. Jeffrey, and P. J. Burke; Bioorg. Med. Chem. Lett. 2020; 30: 127241. https://doi.org/10.1016/j.bmcl.2020.127241.

Peptide Macrocycle Inhibitor of Coagulation Factor XII with Subnanomolar Affinity and High Target Selectivity. S. J. Middendorp, J. Wilbs, C. Quarroz, S. Calzavarini, A. Angelillo-Scherrer, and C. Heinis; J. Med. Chem. 2017; 60: 1151-1158. https://doi.org/10.1021/acs.jmedchem.6b01548.

Structure-activity relationship study of the tumour-targeting peptide A20FMDV2 via modification of Lys16, Leu13, and N- and/or C-terminal functionality. K.-y. Hung, P. W. R. Harris, A. Desai, J. F. Marshall, and M. A. Brimble; Eur. J. Med. Chem. 2017; 136: 154-164. https://doi.org/10.1016/j.ejmech.2017.05.008.

Lead Optimization Yields High Affinity Frizzled 7-Targeting Peptides That Modulate Clostridium difficile Toxin B Pathogenicity in Epithelial Cells. S. Hansen, A. H. Nile, S. C. Mehta, J. Fuhrmann, and R. N. Hannoush; J. Med. Chem. 2019; 62: 7739-7750. https://doi.org/10.1021/acs.jmedchem.9b00500.

Peptidomimetic ethyl propenoate covalent inhibitors of the enterovirus 71 3C protease: a P2-P4 study. M. J. Ang, Q. Y. Lau, F. M. Ng, S. W. Then, A. Poulsen, Y. K. Cheong, Z. X. Ngoh, Y. W. Tan, J. Peng, T. H. Keller, J. Hill, J. J. Chu, and C. S. B. Chia; J. Enzyme Inhib. Med. Chem. 2016; 3: 332-339. https://doi.org/10.3109/14756366.2015.1018245.

Enhanced antimalarial activity of plasmepsin V inhibitors by modification of the P2 position of PEXEL peptidomimetics. W. Nguyen, A. N. Hodder, R. Bestel de Lezongard, P. E. Czabotar, K. E. Jarman, M. T. O’Neill, J. K. Thompson, H. J. Sabroux, A. F. Cowman, J. A. Boddey, B. E. Sleebs; Eur. J. Med. Chem. 2018; 154: 182-198. https://doi.org/10.1016/j.ejmech.2018.05.022.